Fig. 6. The survival of ovarian cancer patients was affected by the methylation status of SLC6A12. Kaplan-Meier analysis of overall survival in patients with serous ovarian cancer. The 5-year survival of patients associated with methylation status of SLC6A12 of <6% methylation versus ≥6% methylation of the 323242 CpG site (A) and 322250 CpG site (B) was compared and the statistical significance between two groups was determined by univariate Cox regression analysis. SLC6A12, solute carrier family 6, member 12.
